Exclusion Criteria
Evolutionary disease requiring an immediate treatment with cytotoxic chemotherapy according to the investigator's judgment.
boolean
Patients with locally advanced breast cancer who are expected to undergo surgery or curative radiotherapy.
boolean
Previous chemotherapy or hormonotherapy for the metastatic disease. Patients may have received neoadjuvant chemotherapy or neoadjuvant hormonotherapy with curative intention as a part or as an alternative to an adjuvant treatment. For the previous neoadjuvant hormonotherapy the same premises than for the adjuvant hormonotherapy are valid.
boolean
Previous therapy with anti-VEGF or VEGFR tyrosine-kinase inhibitors.
boolean
History of another pathology that may affect the development of the protocol or the interpretation of results. It is considered that patients who have suffered from a skin carcinoma that is not melanoma, cervical carcinoma in situ or another neoplasia treated with a curative intention and with a disease-free interval exceeding 5 years can be chosen.
boolean
Evidence of CNS metastasis. A CT scan or brain NMR must be done within the 4 weeks before the randomization in case of suspecting brain metastasis.
boolean
History or evidence in the physical or neurological examination of CNS pathology unrelated to cancer unless it is suitable treated with standard therapy (e.g. uncontrolled convulsions).
boolean
History of peripheral neuropathy NCI CTCAE grade >2 at the time of randomization.
boolean
Patients subjected to major surgical procedures, open biopsies or those having significant trauma injuries within the 28 days prior to randomization, or patients who are expected to undergo a major surgical procedure that must necessarily be performed within the course of the study.
boolean